Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) × CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma cells, is approved for the treatment of patients with relapsed/refractory multiple myeloma (R/RMM). As a T-cell redirection therapy...

Full description

Bibliographic Details

Published in:	Blood Vol. 144; no. 6; p. 615
Main Authors:	Cortes-Selva, Diana, Perova, Tatiana, Skerget, Sheri, Vishwamitra, Deeksha, Stein, Sarah, Boominathan, Rengasamy, Lau, Onsay, Calara-Nielsen, Karl, Davis, Cuc, Patel, Jaymala, Banerjee, Arnob, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, Goldberg, Jenna, Pei, Lixia, Trancucci, Danielle, Girgis, Suzette, Wang Lin, Shun Xin, Wu, Liviawati S, Moreau, Philippe, Usmani, Saad Z, Bahlis, Nizar J, van de Donk, Niels W C J, Verona, Raluca I
Format:	Journal Article
Language:	English
Published:	United States 08.08.2024
Subjects:	Aged Antibodies, Bispecific - therapeutic use B-Cell Maturation Antigen - immunology Female Humans Male Middle Aged Multiple Myeloma - drug therapy Multiple Myeloma - immunology Multiple Myeloma - pathology Multiple Myeloma - therapy
ISSN:	1528-0020, 1528-0020
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!